The White House is expected to announce a deal this week with Eli Lilly and Novo Nordisk that would lower the price of their popular obesity drugs to $149 per month in some cases, according to four people familiar with the agreement who spoke on the condition of anonymity to preview the deal.

The drugs would also be covered for some Medicare beneficiaries, potentially expanding access to the medication for millions of Americans, the people said. Medicare can cover Novo Nordisk’s Ozempic and Wegovy to treat diabetes and Eli Lilly’s Zepbound for sleep apnea, but the coverage does not extend to weight loss.

An announcement could come as soon as Thursday, with President Donald Trump expected to personally tout the deal as part of his ongoing efforts to lower drug prices, one of the people sa

See Full Page